Baseline characteristics of patients with rheumatic diseases exposed to TNF antagonists
| All diseases | Rheumatoid arthritis | |
|---|---|---|
| N | 4655 | 2562 |
| Women (n (%)) | 2910 (63) | 2045 (80) |
| Mean (SD) age (years) | 50 (14) | 54 (13) |
| Mean (SD) disease duration (years) | 11 (9) | 10 (8) |
| Rheumatoid factor positive (n (%)) | 2341 (91) | |
| Mean (SD) DAS28 | 5.5 (1.3) | |
| Methotrexate use (n (%)) | 2078 (45) | 1282 (50) |
| Other DMARD use (n (%)) | 463 (10) | 190 (7) |
| Corticosteroid use (n (%)) | 1770 (38) | 1240 (48) |
DAS28, disease activity score; DMARD, disease-modifying antirheumatic drug; TNF, tumour necrosis factor.